Pnpla3 Silencing with Antisense Oligonucleotides Ameliorates Nonalcoholic Steatohepatitis and Fibrosis in Pnpla3 I148M Knock-in Mice
ConclusionThis study provides the first evidence that a Pnpla3 ASO therapy can improve all features of NAFLD, including liver fibrosis, and suppress the expression of a strong innate genetic risk factor, Pnpla3 148M, which may open up a precision medicine approach in NASH.
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
More News: Diets | Endocrinology | Fatty Liver Disease (FLD) | Genetics | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Study | Urology & Nephrology